paper proposes utilization 225ac cancer isotope decays radioactive NUMBER days cascade alpha isotopes addition indicated pharmacokinetic requirements particular clinical applications 213bi radioactive NUMBER min chosen alternative source radioimmunotherapy isotope alpha emitter 225ac extracted 225ac source bedside patient 225ac quasi ad infinitum obtained precursors 229th available various means indications use alternative traditional classes radiation derived characteristics radioactive source isotope properties carrier moiety source isotope expected useful applications complementary conjunction means therapy identified alpha radioimmunotherapy half life short lived beta emitting half life alpha particles decay cascade alpha particles particle kinetic half life target selective